Table 2.
Antibodies characterized in this study
| Mab | Immunogen | Specificity | Epitope Site | Residues | Ref |
|---|---|---|---|---|---|
| 904 | HBeAg/serum | HBeAg/a | NDa | - | |
| 905 | HBeAg/serum | HBeAg/b | ND | - | |
| 3105 | Virions/serum | HBcAg/α | Spike tip | (77-80)+(77-80)b | 25 |
| 3120 | Virions/serum | HBcAg/β | Capsid; inter-dimer | (20-22)+(25-29)+(126-127) + (20-22)+(129-132)c | 26 |
| F11A4 | rHBcAg/E. coli | HBcAg | Spike tip | (74-77)+(78-80)+(83-84)d | 25 |
| e6 | dHBcAge | HBeAg/β | Dimer; C-terminus | (124-132)f |
a
Not determined.
b
Mab 3105 can bind to the epitope in either of two symmetrical orientations.
c
Mab 3120 binds at the interface between two dimers, involving similar sets of residues on the two subunits.
d
Mab F11A4 binds to both loops and one helix of the four-helix bundle.
e
Reduced and denatured recombinant HBcAg.
f
Approximate extent, from residues identified in this study.